The dual IL-6 and VEGF inhibition of KSI-101 seems to confer additional visual benefits in patients with MESI, with ~half of patients achieving a ≥15-letter improvement 81 Preliminary results. As the APEX study is ongoing, final results may be different due to additional data collection or data cleaning. Includes only patients in the per protocol set that completed the Week 12 visit by the cutoff date of 14-Jul-25 and meet all the eligibility criteria. Excludes one patient in the 10 mg dose with a significant epiretinal membrane at baseline (exclusion criterion) APEX KS1-101 ≥15 letter gainers in patients completing Week 12 33 63 50 48 0 20 40 60 80 100 2.5 mg (n=9) 5 mg (n=8) 10 mg (n=10) All patients (n=27) Patients, %